Ticker LaunchIPO · PAND
Pandion Therapeutics, Inc.
Formerly Pandion Therapeutics Holdco LLC
Pandion Therapeutics, Inc. (PAND) priced its initial public offering on Jul 17, 2020 at $18.00 per share, raising $135M, and listed on Nasdaq Global Select. Goldman Sachs was lead-left underwriter, joined by Morgan Stanley, Leerink Partners and BMO Capital Markets. WilmerHale advised the company and Goodwin Procter advised the underwriters.
Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for autoimmune diseases using its TALON protein design platform. Its lead candidate, PT101, pairs an interleukin-2 mutein effector module with a protein backbone and is designed to selectively expand regulatory T cells.
- Status
- IPO
- Ticker
- PAND
- Exchange
- Nasdaq Global Select
- Priced
- Jul 17, 2020
- IPO price
- $18.00
- Raised
- $135M
- First filed
- Jun 26, 2020
- Underwriters
- Goldman Sachs, Morgan Stanley, Leerink Partners and BMO Capital Markets
- Company counsel
- WilmerHale
- Underwriters' counsel
- Goodwin Procter
- Sector
- Biotech & pharma
- Country / state
- MA
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jun 26, 2020
- Latest amendment Jul 16, 2020
- Final prospectus (424B4) Jul 17, 2020
- All filings on EDGAR CIK 1807901
Other Biotech & pharma IPOs in 2020
- Annexon, Inc.ANNX · Jul 24, 2020 · $250.8M
- ALX Oncology Holdings IncALXO · Jul 17, 2020 · $161.5M
- Relay Therapeutics, Inc.RLAY · Jul 16, 2020 · $400M
- Inventiva S.A.IVA · Jul 13, 2020 · $107.7M
- Nkarta, Inc.NKTX · Jul 13, 2020 · $252M
- Poseida Therapeutics, Inc.PSTX · Jul 10, 2020 · $224M